| United States | |
| 15 | |
| Focuses on the development of antibody therapeutics to address medical needs in the treatment of inflammatory diseases and cancer. | |
| AmiKet contains a combination of amitriptyline and ketamine in a topical formulation. The combination of amitriptyline and ketamine in a cream have been shown to synergistically act to relieve neuropathic pain at the local level. AmiKet has previously been administered to 1700 patients in nine Phase I/II clinical trials. This includes three successfully completed Phase II studies in more than 600 patients with PHN, which demonstrated statistically significant pain reduction and non-inferiority to high dose gabapentin (a commonly used anti-convulsant). Bertilimumab is a fully human, IgG4-type monoclonal antibody (mAb) that blocks the activity of a protein called eotaxin-1 that plays an important role in inflammation in multiple clinical indications. Currently in Phase II development. |
|
| TEPER Daniel | |
| www.immunepharma.com | |
| IMNP:US |
Fiche créée le 10/04/2016 par 
Guillaume vue 9 fois.